Search. IT DOES ALL ITS OWN STUNTS. Investor News Annual Report Governance Reports and Downloads Financial Calendar. Crofelemer, the active ingredient in Mytesi, comes from the Croton lechleri tree, which is responsibly and sustainably harvested in South America. REGISTERED IN ENGLAND NO: 1672070, Enhancing Education, Skills and Well-Being. Investor Information Investor Relations Contact. Search By Business Area, Location or Language. Mytesi (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Live webcast on the investor relations section of Jaguar's website . Mytesi, a novel non-opiate, plant-based, chloride ion channel modulating antidiarrheal medicine, is currently commercialized for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy. For more information about Napo, visit www.napopharma.com. In some cases, you can identify forward-looking statements by terms such as 'may,' 'will,' 'should,' 'expect,' 'plan,' 'aim,' 'anticipate,' 'could,' 'intend,' 'target,' 'project,' 'contemplate,' 'believe,' 'estimate,' 'predict,' 'potential' or 'continue' or the negative of these terms or other similar expressions. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. secretory diarrhea. Company management believes that non-GAAP EBITDA and non-GAAP Recurring EBITDA are meaningful indicators of Jaguar's performance and provide useful information to investors regarding the Company's results of operations and financial condition. JAGUAR I-PACE NOW SMARTER, BETTER CONNECTED AND FASTER-CHARGING. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity. Download Investor day 2018. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. Minimum 15 minutes delayed. The forward-looking statements in this release are only predictions. Peter Hodge If you are interested in www.streetinsider.com content, APIs are available. Slavery and Human Trafficking Statement, REGISTERED OFFICE: ABBEY ROAD, WHITLEY, COVENTRY, CV3 4LF. Image. Full Story. The Investor Relations website contains information about Jaguar Health, Inc.'s business for stockholders, potential investors, and financial analysts. Investor Relations. TSX:JAG Peter HodgeJaguar Health, Inc.phodge@jaguar.healthJaguar-JAGX, Jaguar Health Subsidiary Napo Pharmaceuticals Completes Filing of Investigational New Drug Application for Crofelemer (Mytesi) for Symptomatic Relief of Cancer Therapy‑Related Diarrhea, Sustainability & Community Benefit Sharing, https://www.accesswire.com/596280/Jaguar-Health-Subsidiary-Napo-Pharmaceuticals-Completes-Filing-of-Investigational-New-Drug-Application-for-Crofelemer-Mytesi-for-Symptomatic-Relief-of-Cancer-TherapyRelated-Diarrhea. Turmalina March 2016. Electrical Distribution System Lead Design Engineer, Electrical Distribution System Group Leader, Product Manager - Software Defined Networking, Assisted & Automated Driving Test Engineer Radars - D Grade, Assisted & Automated Driving Test Case Engineer - D Grade, Assisted & Automated Driving Test Engineer Low Speed Manoeuvring - C Grade, Assisted & Automated Driving Test Engineer Low Speed Manoeuvring - D Grade, Jaguar Investor Relations at Jaguar Land Rover. http://www.streetinsider.com/signup_content.php. Our Portfolio Companies. A significant proportion of patients undergoing cancer therapy experience diarrhea. Media . Investor Relations The automotive industry in experiencing unprecedented challenges, with the weak market conditions in China and signs of weaker industry conditions in other markets; geopolitical uncertainty with rising populism, tariff and trade tensions and not to mention Brexit in the UK. REGISTERED OFFICE: ABBEY ROAD, WHITLEY, COVENTRY, CV3 4LF. Our wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. These include statements regarding the expectation that Jaguar will host an investor call on November 16, 2020. Just enter your e-mail address and click Submit. Distributed by Public, unedited and unaltered, on 16 November 2020 13:06:01 UTC, Net loss attributable to common shareholders, Contract manufacturer's fee charged for canceling a Mytesi production run, Distribution fees from former distributor, Reversal of accrued royalty due to termination of royalty agreement, https://www.accesswire.com/616798/Jaguar-Health-Inc-Reports-2020-Third-Quarter-Financial-Results, President, Chief Executive Officer & Director, Chief Financial & Accounting Officer, SVP-Finance. Additionally, gross sales may not be comparable to similarly titled measures used by other companies, as gross sales have been defined by the Company's internal reporting practices. Jaguar has based these forward-looking statements largely on its current expectations and projections about future events. Home; About Jaguar; Services; Insights; Investor Relations; Careers; Contact Us; P.O. Napo has established a sustainable harvesting program for crofelemer to ensure a high degree of quality and ecological integrity. Certain statements in this press release constitute 'forward-looking statements.' Our Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and the only oral plant-based prescription medicine approved under FDA Botanical Guidance. Gross sales is not a measure that is recognized under accounting principles generally accepted in the United States of America ('GAAP') and should not be considered as an alternative to net sales, which is determined in accordance with GAAP, and should not be used alone as an indicator of operating performance in place of net sales. Investors. Box 303. Full Story . Gross sales percentages are based on gross sales figures that represent Mytesi orders placed by wholesalers with Jaguar's third-party logistics warehouse, which generate invoiced sales and cash flow for Napo. Jaguar-JAGX, Jaguar Health Inc. published this content on 16 November 2020 and is solely responsible for the information contained therein. As you were browsing www.streetinsider.com something about your browser made us think you were a bot. Jaguar believes that the disclosure items of these non-GAAP measures provide investors with additional information that reflects the basis upon which Company management assesses and operates the business. Download UNICREDIT CONFERENCE 6 JUNE 2018 ... Jaguar Land Rover is part of Tata Motors. JAGUAR LAND ROVER AUTOMOTIVE PLC Third quarter 2020 Mytesi net sales and gross sales were approximately $2.8 million and approximately $6.3 million, respectively Company to host investor call Monday, November... | November 16, 2020 Toronto, Ontario M5X 1C9 Office: +1 416.847.1854 Email: ir@jaguarmining.com.br. Crofelemer, the active ingredient in Mytesi, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon rainforest. For more information about Napo, visit www.napopharma.com. NEW LAND ROVER DEFENDER. The Company believes that the presentation of gross sales provides a closer to real-time useful measure of our operating performance. Investor Information Investor Relations Contact. SAN FRANCISCO, CA / ACCESSWIRE / November 16, 2020 /Jaguar Health, Inc. (NASDAQ:JAGX) ('Jaguar' or the 'Company') today reported consolidated third quarter 2020 financial results. For more information about Jaguar, please visit https://jaguar.health. Our wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals for the global marketplace from plants used traditionally in rainforest areas. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%). For more information about Jaguar, please visit https://jaguar.health. Sustainability & Community Benefit Sharing, Jaguar Health, Inc. Reports 2020 Third Quarter Financial Results, Jaguar Health to Host Investor Call Monday, November 16th at 8:30 a.m. Eastern Regarding Q3 2020 Financials & Business Updates, Jaguar Health Receives Positive Nasdaq Listing Determination, Reminder: Jaguar Health Hosting Exclusive Virtual Educational Event, "Diarrhea Dialogues: Why Bowel Control is Critical to Supportive Care in Cancer". These non-GAAP financial measures are not in accordance with GAAP and should not be viewed in isolation or as substitutes for GAAP net sales and GAAP net loss and are not substitutes for, or superior to, measures of financial performance in conformity with GAAP. Jaguar Mining: Gold Producer in Brazil’s Largest Mining State. Our Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and the only oral plant-based prescription medicine approved under FDA Botanical Guidance. REGISTERED IN ENGLAND NO: 1672070, Jaguar Land Rover is part of Tata Pacheca Geophysics Survey. Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, sustainably derived gastrointestinal products on a global basis. * In ‘Nepse vs Jaguar’, Jaguar’s returns are marked to market. The Company supplements its condensed consolidated financial statements presented on a GAAP basis by providing gross sales, non-GAAP EBITDA and non-GAAP recurring EBITDA, which are considered non-GAAP under applicable SEC rules. First Canadian Place 100 King Street West, 56th Flr. Jaguar Health, Inc.phodge@jaguar.health In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%). Please contact us here http://www.streetinsider.com/signup_content.php. The automotive industry in experiencing unprecedented challenges, with the weak market conditions in China and signs of weaker industry conditions in other markets; geopolitical uncertainty with rising populism, tariff and trade tensions and not to mention Brexit in the UK. Download SEPT 2018 BOND CONFERENCE. … JAGUAR LAND ROVER EXPANDS ELECTRIFIED LINE-UP WITH THREE-CYLINDER PLUG-IN HYBRID. Our wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest areas. You reached this page when attempting to access https://www.streetinsider.com/Accesswire/Jaguar+Health+to+Host+Investor+Call+Monday%2C+November+16th+at+8%3A30+a.m.+Eastern+Regarding+Q3+2020+Financials+%26+Business+Updates/17582937.html from 66.198.240.31 on 2020-11-18 10:41:03 UTC. A significant proportion of patients undergoing cancer therapy experience diarrhea. We have learned from business development discussions with cancer drug manufacturers that adoption and continued use of targeted cancer therapies is directly related to the ability of patients to tolerate use of the therapies - highlighting the importance of supportive care drugs like Mytesi to help manage cancer treatment-related diarrhea in this patient population.". The Investor Relations website contains information about Jaguar Health, Inc.'s business for stockholders, potential investors, and financial analysts. Investor Relations. For more information about Jaguar, please visit https://jaguar.health. Mytesi is not indicated for the treatment of infectious diarrhea. Jaguar Corporate Video (English) - February 2017. Jaguar Investor Relations at Jaguar Land Rover; JAGUAR LAND ROVER JOB SEARCH At the moment this job search page is for selected opportunities only (UK, Ireland, Slovakia and Hungary). Mytesi (crofelemer) is an antidiarrheal indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Certain statements in this press release constitute "forward-looking statements." Sign up to receive e-mail alerts whenever Jaguar Health, Inc. posts new information to the site. Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Motors. Novel "targeted cancer therapy" agents, such as epidermal growth factor receptor (EGFR) antibodies and tyrosine kinase inhibitors (TKIs), with or without cycle chemotherapy agents, may activate intestinal chloride ion channel-mediated secretory pathways leading to increased electrolyte and fluid content in the gut lumen, which results in passage of loose/watery stools, i.e. The Company defines non-GAAP Recurring EBITDA as non-GAAP EBITDA adjusted for certain non-recurring revenues and expenses. JLR Investor Relations Presentation September 2018. About Jaguar Health, Inc. and Napo Pharmaceuticals, Inc. Jaguar Health, Inc. is a commercial stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. These forward-looking statements speak only as of the date of this release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. HRH THE PRINCE OF WALES OFFICIALLY OPENS THE NATIONAL AUTOMOTIVE INNOVATION CENTRE, BESTSELLING EVOQUE AND DISCOVERY SPORT SUVS NOW AVAILABLE AS PLUG-IN HYBRIDS WITH ALL-ELECTRIC RANGE OF UP TO 66KM, JAGUAR LAND ROVER UNVEILS FUTURE OF URBAN MOBILITY, JAGUAR LAND ROVER SCALES UP FACE VISOR PRODUCTION FOR NHS STAFF FIGHTING CORONAVIRUS, TALENTED FEMALE STUDENTS INSPIRED TO FURTHER THEIR FUTURES, JAGUAR LAND ROVER EXPANDS ELECTRIFIED LINE-UP WITH THREE-CYLINDER PLUG-IN HYBRID. In addition, gross sales may not be realized in the form of cash receipts as promotional payments and allowances may be deducted from payments received from certain customers. The Investor Relations website contains information about Jaguar Health, Inc.'s business for stockholders, potential investors, and financial analysts. Third quarter 2020 Mytesi net sales and gross sales were approximately $2.8 million and approximately $6.3 million, respectively, Company to host investor call Monday, November 16th at 8:30 a.m. Eastern regarding third quarter 2020 financials & business updates. Crofelemer, the active ingredient in Mytesi, is a botanical (plant-based) drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree in the Amazon Rainforest. Mytesi is not indicated for the treatment of infectious diarrhea. See full Prescribing Information at Mytesi.com. * In ‘Nepse vs Jaguar’, Jaguar’s returns only indicate the performance of it's stock portfolio. In the third quarter of 2020, the Company's animal product commercialization efforts were intentionally minimal, and Jaguar's animal-related sales were also minimal. SAN FRANCISCO, CA / ACCESSWIRE / July 6, 2020 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") announced today that the Company's wholly owned subsidiary Napo Pharmaceuticals, Inc. ("Napo") has completed the filing of the investigational new drug application (IND) with the U.S. Food and Drug Administration (FDA) for crofelemer (Mytesi®) for the planned indication of prophylaxis and symptomatic relief of diarrhea in adult patients with solid tumors receiving targeted therapy with or without standard chemotherapy ("cancer therapy‑related diarrhea" (CTD)). Some of the factors that could affect our actual results are included in the periodic reports on Form 10-K and Form 10-Q that we file with the Securities and Exchange Commission. Toronto, Ontario M5X 1C9 Office: +1 416.847.1854 The Company defines non-GAAP EBITDA as net loss before interest expense and other expense, property and equipment, amortization of intangible assets, share-based compensation expense and provision for or benefit from income taxes. We anticipate these challenges to continue, however we expect Project Charge, Accelerate and a strong pipeline of new products to produce improvements in our business performance. The forward-looking statements in this release are only predictions. "Many cancer patients on targeted therapy require drug holidays or dose reductions in their therapy due to diarrhea," Lisa Conte, Jaguar's president and CEO, stated. JavaScript needs to be enabled to complete CAPTCHA. About Jaguar Health, Inc. and Napo Pharmaceuticals, Inc. "Reducing frequency of watery stools will provide symptomatic relief of diarrhea and should allow better adherence to the therapeutic dosing of any targeted therapies, potentially leading to better clinical outcomes. Search. Our Mytesi® (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy and the only oral plant-based prescription medicine approved under FDA Botanical Guidance. See full Prescribing Information at Mytesi.com. Data Provided by Refinitiv. Pilar Gold Mine March 2016 . After completing the CAPTCHA below, you will immediately regain access to www.streetinsider.com. By continuing to use and navigate this website, you are agreeing to the use of cookies. When: Monday, November 16, 2020 at 8:30 a.m. Eastern Time, Live webcast on the investor relations section of Jaguar's website (click here), Replay of the webcast on the investor relations section of Jaguar's website (click here). The automotive industry in experiencing unprecedented challenges, with the weak market conditions in China and signs of weaker industry conditions in other markets; geopolitical uncertainty with rising populism, tariff and trade tensions and not to mention Brexit in the UK. Rule out infectious etiologies of diarrhea before starting Mytesi. Jaguar Corporate Video (Portuguese) - February 2017. If infectious etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and their disease may worsen. For more information about Napo, visit www.napopharma.com. 2020 Third Quarter Company Financial Results: The increase in sales coincided with enhancements to the Mytesi patient access program, known as NapoCares™, of Jaguar's wholly owned subsidiary, Napo Pharmaceuticals, Inc., in the beginning of April 2020. These forward-looking statements speak only as of the date of this release and are subject to several risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond Jaguar's control. Except as required by applicable law, Jaguar does not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Investor Information; News Releases; SEDAR; ESTMA; Financial Reports; Analyst Coverage; Presentations & Media. The Investor Relations website contains information about Jaguar Health, Inc.'s business for stockholders, potential investors, and financial analysts. Gross sales are used internally by management as an indicator of and to monitor operating performance, including sales performance of Mytesi, salesperson performance, and product growth or declines. Corporate Media Jaguar Media Land Rover Media Twitter. Rule out infectious etiologies of diarrhea before starting Mytesi. Mytesi gross sales are reduced by Medicare, ADAP 340B chargebacks, returns, and wholesale distribution fees based on historical trends to determine net sales. These include statements regarding the development of crofelemer for the potential additional indication of symptomatic relief of CTD, and the expectation that reducing frequency of watery stools in cancer patients will allow better adherence to the therapeutic dosing of any targeted therapies, potentially leading to better clinical outcomes. In some cases, you can identify forward-looking statements by terms such as "may," "will," "should," "expect," "plan," "aim," "anticipate," "could," "intend," "target," "project," "contemplate," "believe," "estimate," "predict," "potential" or "continue" or the negative of these terms or other similar expressions. First Canadian Place 100 King Street West, 56th Flr. CEO Interview.